03/06
Headlines

NASDAQ:ZIOP

Gilead Sciences GILD NASDAQ:GILD

Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

Kristen Barton02 mins

MannKind Corporation (NASDAQ:MNKD) announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA(R) by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA’s requests.MannKind Corporation (NASDAQ:MNKD) stock performance…

Read More
FB Nasdaq FB Facebook

Biotech losers: ZIOPHARM Oncology (NASDAQ:ZIOP), Sangamo Biosciences (NASDAQ:SGMO), Lexicon Pharmaceuticals (NASDAQ:LXRX), XOMA Corp (NASDAQ:XOMA)

Colin Pettis02 mins

On Apr 3, Zacks Investment Research upgraded ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to Zacks Rank #1 (Strong Buy). ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s loss estimates have declining on the back of better-than-expected fourth quarter 2013 results. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock performance was -6.06% in last session and finished the day at $4.34. Traded volume was 1.86million…

Read More

Volatile Stocks at Biotech: ZIOPHARM Oncology (NASDAQ:ZIOP), Idenix Pharmaceuticals (NASDAQ:IDIX), Synthetic Biologics (NYSEMKT:SYN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Kristen Barton03 mins

Looking back to 160 days ago, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) priced a 14,300,000 share secondary stock offering at $3.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Wednesday. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)…

Read More